Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
A Prospective, Randomized, International, Multicenter, Double-arm, Controlled, Open-label Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Are on a Stable Dose of Phosphodiesterase-5 Inhibitors (PDE-5i) With or Without Endothelin Receptor Antagonist (ERA), But Not at Treatment Goal A Prospective, Randomized, International, Multicenter, Double-arm, Controlled, Open-label Study of R ...
United States;Austria;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;Australia;Switzerland United States;Austria;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, ...
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension. A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertensio ...
An Open-label, Multi-national, Multi-center, Single-arm, Uncontrolled, Long-term Extension Study of Orally Administered Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH) Who Received Riociguat in a Bayer Clinical Trial An Open-label, Multi-national, Multi-center, Single-arm, Uncontrolled, Long-term Extension Study of ...